The National Lipid Association (NLA) and the American College of Cardiology (ACC) recently provided recommendations to help us achieve optimal low-density lipoprotein (LDL) levels in statin-intolerant patients, but what other management strategies are available? Joining Dr. Charles Turck to answer this question and to give more key insights is Dr. Yehuda Handelsman, Medical Director and Principal Investigator at the Metabolic Institute of America.